. . . . . . . . . . . . . . . . "tscript(p(HGNC:NFYB)) => r(HGNC:CD34)" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "Figure 5B shows that addition of either of the two anti-NFYA antibodies to the binding reactions supershifted a prominent complex (lanes 3 and 4) and the anti-NFYB antibody diminished binding significantly (lane 5). To test the functional effect of NFY binding to the +60/+64 region, we introduced point mutations abolishing the binding of NFY to its site (see Fig 5A and Fig 5B; lane 14) and incorporated them into a luciferase plasmid containing base pairs -391/+175 from the human CD34 promoter (constructs diagramed in Fig 5C). As shown in Fig 5D, mutating the NFY site (Y-M+ construct) resulted in a 5-fold decrease in luciferase activity in transiently transfected KG1a cells and a 4-fold decrease in RPMI-8402 cells, as compared with the wild-type construct (Y+M+ construct)." . . "Selventa" . . . . "2014-07-03T14:29:49.325+02:00"^^ . . .